Compare ING Groep NV (ING) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Johnson & Johnson — how do they compare? ING Groep NV trades at $33.37 (market cap $93.76B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 6.6× ING Groep NV's market cap, and ING Groep NV pays the higher dividend (3.95%). Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and Johnson & Johnson for 129 Days on average.
| ING | JNJ | |
|---|---|---|
Market Cap | $93.76B | $618.09B |
Volume | 4,620,220 | 6,050,983 |
Sector | Financials | Health |
52-Week High | $37.27 | $278.43 |
52-Week Low | $23.66 | $186.00 |
Typical Hold Time | 94 Days | 129 Days |
Enterprise Value | $236.48B | $646.37B |
Dividend Yield | 3.95% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING stock trades at $33.43, down 1.44% with a bearish technical outlook. The company shows strong fundamentals with consistent earnings beats, a 28.34% net margin, and positive analyst sentiment (64.71% buy ratings). Recent news highlights management's raised ROE target to 16% for 2027 and upgraded revenue guidance, though cash flow trends remain negative.
The outlook is cautiously optimistic given strong profitability and growth initiatives, but risks include persistent negative cash flows and regulatory scrutiny in Australia. The stock presents value with a reasonable P/E of 12.86, supported by dividend payments and institutional confidence.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
